| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1629
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate |
2007-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a98b585cec0a00abadffb372f5a24d23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67747b152418db571c45700b5ed92075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_004b7452fa8863be899851d12dab2d8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38df4c9808f71ba7725e7b6cbe743db5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28f31a9c9396b7d2331e9754d3313d62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15c1100c13a3135b2b5a4e02a8698fa3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9393652a30d3fd83bd4a138e85a6993 |
| publicationDate |
2007-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NO-20070779-L |
| titleOfInvention |
Pharmaceutical dosage forms comprising a low-soluble drug and a polymer |
| abstract |
There is disclosed a dosage form comprising a low-solubility drug and a precipitation-inhibiting polymer. The drug is in a solubility-enhanced form and in the form of particles which are at least partially coated with the precipitation-inhibiting polymer. Representative low-solubility drugs are ziprasidone and sildenafil. Representative precipitation inhibiting polymer is HPMCAS. |
| priorityDate |
2004-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |